期刊
BIOMEDICINES
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10020274
关键词
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; chronic liver disease; hepatoprotection; metabolic disorders
资金
- Analytics and Devices Ltd. (St. Petersburg, Russia)
This paper provides an update on the rapidly changing therapeutic landscape of non-alcoholic fatty liver disease (NAFLD). It highlights the major novel approaches to the treatment of this disease and reviews the current status of drug discovery and development pipeline, focusing on recent evidence from clinical trials.
Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据